Literature DB >> 10580119

Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNgamma-induced release of NO and TNFalpha.

R Pellizzari1, C Guidi-Rontani, G Vitale, M Mock, C Montecucco.   

Abstract

The lethal toxin of Bacillus anthracis consists of two proteins, PA and LF, which together induce lethal effects in animals and cause macrophage lysis. LF is a zinc-endopeptidase which cleaves two mitogen-activated protein kinase kinases (MAPKKs), Mek1 and Mek2, within the cytosol. Here, we show that also MKK3, another dual-specificity kinase that phosphorylates and activates p38 MAP kinase, is cleaved by LF in macrophages. No direct correlation between LF-induced cell death and cleavage of these MAPKKs was found in macrophage cell lines and primary peritoneal cells exhibiting different sensitivity to LF. However, we present the first evidence that sublytic doses of LF cleave Meks and cause a substantial reduction in the production of NO and tumour necrosis factor-alpha induced by lipopolysaccharide/interferon gamma. We suggest that this effect of LF is relevant during the first stages of B. anthracis infection, when a reduction of the inflammatory response would permit growth and diffusion of the bacterium.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10580119     DOI: 10.1016/s0014-5793(99)01502-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  102 in total

1.  Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin.

Authors:  J Mogridge; M Mourez; R J Collier
Journal:  J Bacteriol       Date:  2001-03       Impact factor: 3.490

2.  Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen.

Authors:  Kristina Cunningham; D Borden Lacy; Jeremy Mogridge; R John Collier
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

Review 3.  New insights into the biological effects of anthrax toxins: linking cellular to organismal responses.

Authors:  Annabel Guichard; Victor Nizet; Ethan Bier
Journal:  Microbes Infect       Date:  2011-09-08       Impact factor: 2.700

4.  Characterization of dominant-negative forms of anthrax protective antigen.

Authors:  Ming Yan; R John Collier
Journal:  Mol Med       Date:  2003 Jan-Feb       Impact factor: 6.354

Review 5.  Regulating caspase-1 during infection: roles of NLRs, AIM2, and ASC.

Authors:  Christopher L Case
Journal:  Yale J Biol Med       Date:  2011-12

6.  Bacillus anthracis endospores regulate ornithine decarboxylase and inducible nitric oxide synthase through ERK1/2 and p38 mitogen-activated protein kinases.

Authors:  Supatra Porasuphatana; Guan-Liang Cao; Pei Tsai; Fatemeh Tavakkoli; Theresa Huwar; Les Baillie; Alan S Cross; Paul Shapiro; Gerald M Rosen
Journal:  Curr Microbiol       Date:  2010-05-04       Impact factor: 2.188

7.  Clostridium sordellii lethal toxin kills mice by inducing a major increase in lung vascular permeability.

Authors:  Blandine Geny; Huot Khun; Catherine Fitting; Leticia Zarantonelli; Christelle Mazuet; Nadège Cayet; Marek Szatanik; Marie-Christine Prevost; Jean-Marc Cavaillon; Michel Huerre; Michel R Popoff
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

8.  Cross-linked forms of the isolated N-terminal domain of the lethal factor are potent inhibitors of anthrax toxin.

Authors:  Stephen J Juris; Roman A Melnyk; Robert E Bolcome; Joanne Chan; R John Collier
Journal:  Infect Immun       Date:  2007-07-16       Impact factor: 3.441

9.  Effect of Bacillus anthracis virulence factors on human dendritic cell activation.

Authors:  Andrew C Hahn; C Rick Lyons; Mary F Lipscomb
Journal:  Hum Immunol       Date:  2008-07-26       Impact factor: 2.850

10.  Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.

Authors:  Alexander N Wein; Shihui Liu; Yi Zhang; Andrew T McKenzie; Stephen H Leppla
Journal:  Invest New Drugs       Date:  2012-07-28       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.